The New York Times examines how longevity medicine is moving toward the mainstream as major health systems launch their own programs, lending the field new credibility and broader access.
Fountain Life is cited as an example of a membership-based longevity company. With five clinics, its highest tier gives members access to whole genome sequencing, whole-body MRI, stem cell therapies and therapeutic plasma exchange, among other assessments and treatments.
Fountain Life Chief Medical Officer Dr. Dawn Mussallem told the Times that some of the therapies the company offers have early, promising data for longevity, adding: “Much of the most important science lives in between.”
.avif)
